GILEAD Aktie

 

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies....

MOUNT GILEAD, N.C., Sept. 4, 2026 /PRNewswire/ -- McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) declared a dividend of $.14 per share on the Company's Class A and Class B Common Stock payable on October 1, 2026 to shareholders of record on September 17, 2026. View original......

Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check....

Mutual Fund Report for ETGLX...

Nach dem starken August nimmt die Assembly Biosciences-Aktie aktuell etwas Tempo heraus und notiert bei 35,84 US$. Die Rally hat den Kurs inzwischen unmittelbar an den Widerstand bei 37 US$ geführt, ohne dass die übergeordnete Aufwärtsdynamik bislang Schaden genommen hätte. Gleichzeitig sorgen mehrere klinische Meilensteine und die Partnerschaft mit Gilead für weitere Fantasie. Vieles spricht […] The post Assembly Biosciences-Aktie: Wann geht es über 40 US$? first appeared on sharedeals.de....

A securities class action alleges that iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) shares climbed from a $4.00 IPO price to $32.00 before collapsing approximately 95% in a single session, with the Company later acknowledging its price had been influenced by false Gilead acquisition......

O'day, Daniel Patrick - Vorstand - Tag der Transaktion: 2026-09-01...

A securities class action alleges iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) was the vehicle for a pump-and-dump manipulation scheme built on fabricated Gilead Sciences acquisition rumors, and that the Company's disclosures never warned of the realized manipulation risk before shares......

Die Neubewertung von Assembly Biosciences gewinnt weiter an Dynamik. Nachdem Partner Gilead Sciences mit der Auswahl von GS-1179 für die Phase 2 und der möglichen Ausweitung des Programms auf Präventionsanwendungen die Perspektive der HSV-Franchise deutlich erweitert hat, folgt nun ein bemerkenswerter Schritt auf Analystenseite: Die UBS hat die Coverage von Assembly Biosciences neu aufgenommen und […] The post Assembly Biosciences-Aktie: UBS startet Coverage mit Ziel 52 US$ – Mizuho erhöht Rating first appeared on sharedeals.de....

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients....

Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies....

NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturin......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Welters, Anthony - Aufsichtsrat - Tag der Transaktion: 2026-08-26...

The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment....

Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines....

Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity....

FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) announced the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of adult patients w......